Romainville, September 21, 2009 - the French genome engineering company Cellectis S.A. (Alternext: ALCLS) has today announced the appointment of Dr Sylvie Delassus as Senior Vice President Communications. She will be a member of Cellectis’ Executive Committee. This decision reflects Cellectis’ commitment to developing an ambitious, strategically coherent corporate communications program.
After entering the Ecole Polytechnique in Paris in 1983 and obtaining her PhD in 1991, Sylvie Delassus (aged 46) spent 11 years (from 1989 to 2000) as a researcher in virology and immunology at the Institut Pasteur in Paris and the Institute of Cancer Research in London. She served as Public Relations Director at the Institut Pasteur from 2000 to 2004 and then as Head of Communications for the R&D subsidiary of Aventis (from 2004 to 2006). Sylvie Delassus then worked at the French Agency for Environmental and Occupational Health and Safety (Afsset) with a special focus on developing the scientific aspects of the agency’s communication and increasing its contribution to public debate.
Her international scientific experience and expertise in communications in a scientific environment will help Cellectis deliver on its stated objectives.
About Cellectis S.A.
Cellectis SA is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery addressing the therapeutic, agricultural biotechnology, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharmaceutical, biotech and agricultural biotechnology industries and has over 20 collaborations with academic research groups. Since its incorporation, Cellectis has raised over 50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
Disclaimer
This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
